Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans

• Published in: The Journal of pathology Vol. 223; no. 3; pp. 425 - 435
• Main Authors: Bellemare, Judith, Rouleau, Mélanie, Harvey, Mario, Popa, Ion, Pelletier, Georges, Têtu, Bernard, Guillemette, Chantal
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01-02-2011; Wiley
• Subjects: Alternative Splicing; Biological and medical sciences; Colonic Neoplasms - enzymology; dominant negative function; Glucuronosyltransferase - metabolism; human tissues; Humans; Intestine, Small - enzymology; Investigative techniques, diagnostic techniques (general aspects); Isoenzymes - metabolism; Kidney - enzymology; Liver Neoplasms - enzymology; Medical sciences; metabolism; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; splice variants; Stomach - enzymology; UDP-glucuronosyltransferase (UGT); Human; Immunohistochemistry; Drug; Alternative splicing; Molecular form; UDP-glucuronosyltransferase; Enzyme; Transferases; Tumoral tissue; Glycosyltransferases; splice variants; Metabolism; Normal; human tissues; Anatomic pathology; dominant negative function; UDP-glucuronosyltransferase (UGT); Recessive character; Genetics; Hexosyltransferases
• ISSN: 0022-3417; 1096-9896
• DOI: 10.1002/path.2805

Glucuronidation by UDP‐glucuronyltransferase (UGT) enzymes is the prevailing conjugative pathway for the metabolism of both xenobiotics and endogenous compounds. Alterations in this pathway, such as those generated by common genetic polymorphisms, have been shown to significantly impact on the health of individuals, influencing cancer susceptibility, responsiveness to drugs and drug‐induced toxicity. Alternative usage of terminal exons leads to UGT1A‐derived splice variants, namely the classical and enzymatically active isoforms 1 (i1) and the novel enzymatically inactive isoforms 2 (i2). In vitro functional data from heterologous expression and RNA interference experiments indicate that these i2 isoforms act as negative modulators of glucuronidation, likely by forming inactive complexes with active isoform 1. We used specific antibodies against either active i1 or inactive i2 proteins to examine their distribution in major drug‐metabolizing tissues. Data revealed that UGT1A_i1 and inactive UGT1A_i2 are co‐produced in the same tissue structures, including liver, kidney, stomach, intestine and colon. Examination of the cellular distribution and semi‐quantitative level of expression of UGT1As revealed heterogeneous expression of i1 and i2 proteins, with increased expression of i2 in liver tumours and decreased levels of i1 and i2 in colon cancer specimens, compared to normal tissues. These differences in expression may be relevant to human colon and liver cancer tumorigenesis. Our data clearly demonstrate the similar immunolocalization of active and inactive UGT1A isoforms in most UGT1A‐expressing cell types of major tissues involved in drug metabolism. These expression patterns are consistent with a dominant‐negative function for the i2 encoded by the UGT1A gene. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.